Clinical trials: Throat Carcinoma
Squamous Cell Carcinoma of Oropharynx
Patients With Human Papillomavirus-associated Head and Neck Cancer for the Discovery of Predictive Biomarkers to Guide Clinical Intervention
Prospective pilot study, non-interventional, of a biological/radiological nature, which involves the collection of tissue samples, and blood from patients suffering from squamous cell carcinoma of the oropharynx OPSCC for…
- Trial name
- NCT06821243
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Regina Elena Cancer Institute
Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of EGFR antibody combined with programmed death 1 (PD-1) antibody and chemotherapy in…
- Conditions
- Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma, Metastatic Nasopharyngeal Carcinoma
- Trial name
- NCT06802835
- Testing
- EGFR Antibody, PD-1 antibody, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
BGT007 Cell Treatment of Nasopharyngeal Carcinoma
This is an exploratory study to evaluate the safety and preliminary effectiveness of BGT007 cells in the treatment of recurrent/metastatic nasopharyngeal carcinoma
- Trial name
- NCT05616468
- Testing
- BGT007 Cell Injection, Fludarabine, cyclophosphamide
- Where
- China
- Volunteers
- 23 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma Post IMRT
Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer. The last three decades of research in head and neck radiation oncology have largely focused on improvements in survival, which have mostly come at the cost of long…
- Trial name
- NCT02597426
- Where
- Canada
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Laryngeal Cancer, Hypopharyngeal Cancer
Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma
The aim of this study is to define whether combination of induction chemotherapy and PD-1 inhibitor (Toripalimab) followed by radiotherapy improve progression-free survival, for patients with unresectable laryngeal/hypopharyngeal…
- Trial name
- NCT05420597
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma
Nedaplatin in Treatment for Nasopharyngeal Carcinoma
To evaluate the efficacy of induction chemotherapy with nedaplatin, docetaxel and 5-Fluorouracil followed by concurrent nedaplatin combined with radical radiotherapy in locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT04834206
- Testing
- Docetaxel, nedaplatin, fluorouracil, IMRT, Nedaplatin
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Metastatic Nasopharyngeal Carcinoma
Metastatic Nasopharyngeal Carcinoma
To evaluaate the efficacy and safety of the regimen incuding Penpulimab, Gemcitabine and Anlotinib in the treatment of metastatic nasopharyngeal carcinoma. Using Progression-Free-Survival as the primary endpoint.
- Trial name
- NCT06886347
- Testing
- Penplimab Injection, Antitinib Hydrochloride Capsules, Gemcitabine
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Chen Xiaozhong
Dysphagia
Multifunctional Nutrition Tube in Dysphagia for Nasopharyngeal Carcinoma
Baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life (QOL) after treatment as well as adverse events are compared.
- Trial name
- NCT06328868
- Testing
- Intermittent Oral-esophageal Tube Feeding, Nasogastric Tube Feeding, comprehensive rehabilitation therapy
- Volunteers
- 80 people
- Sponsor
- Copka Sonpashan
Nasopharyngeal Carcinoma, PD-1 Inhibitors
PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial
programmed cell death-1 (PD-1) inhibitors has been recommended as the first-line treatment for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), but progression-free survival (PFS) and overall survival (OS) was still…
- Conditions
- Nasopharyngeal Carcinoma, PD-1 Inhibitors, Chemoradiotherapy
- Trial name
- NCT05520814
- Testing
- PD-1 inhibitors, chemoradiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Nasopharyngeal Carcinoma
Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma
This trial plans to enroll patients with stage III-IVA (AJCC 8th, included T1-2N2-3 and/or T3-4N0-3 M0) locoregionally-advanced nasopharyngeal carcinoma (LANPC).
- Trial name
- NCT05097209
- Testing
- Camrelizumab, Gemcitabine, Induction Cisplatin
- Where
- 5 sites in China
- Volunteers
- 200 people
- Sponsor
- Wei Jiang
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck
Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
This clinical trial tests the impact of offering hearing tests (audiometry) close to home and remotely on participation in monitoring for treatment-related hearing loss in patients with head and neck squamous cell cancer…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06662058
- Testing
- Audiometric Test, Interview
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Emory University
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal HPV-Positive Squamous Cell Carcinoma
Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
This phase II trial tests whether reduced dose radiation therapy after transoral robotic surgery works in treating patients with human papillomavirus (HPV)-positive oropharyngeal cancer.
- Trial name
- NCT05387915
- Testing
- Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Emory University
Nasopharyngeal Carcinoma
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
To estimate the efficacy and safety of tislelizumab for stage IVA locally advanced nasopharyngeal carcinoma combined with induction chemotherapy and concurrent chemoradiotherapy, followed by maintenance therapy
- Trial name
- NCT05448885
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nasopharyngeal Carcinoma
Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma
Standard of care for treatment of nasopharyngeal carcinoma is chemoradiation with concurrent cisplatin. Addition of a second agent, cetuximab, which targets nasopharyngeal carcinoma cells with high EGFR protein expression, may…
- Trial name
- NCT01230476
- Testing
- Cetuximab
- Where
- Malaysia
- Volunteers
- 3 people
- Sponsor
- University of Malaya
Oropharynx Cancer, Larynx Cancer
Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
The aim of this study is to investigate the effect of ATRA (Vesanoid) and the effect of tailored radiotherapy in patients with squamous cell carcinoma of the oropharynx, larynx or hypopharynx.
- Conditions
- Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Primary Head and Neck Tumor
- Trial name
- LYSARI (NCT06706401)
- Testing
- Vesanoid, Standard radiotherapy, Tailored radiotherapy
- Where
- 8 sites in France
- Volunteers
- 460 people
- Sponsor
- Centre Leon Berard
Nasopharyngeal Carcinoma (NPC)
A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
The study is to explore the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic Nasopharyngeal Carcinoma (NPC) who failed or are intolerant to…
- Trial name
- NCT06839066
- Testing
- HLX43 DOSE 1, HLX43 DOSE 2, HLX43 DOSE 3
- Where
- 15 sites in China
- Volunteers
- 70 people
- Sponsor
- Shanghai Henlius Biotech
Larynx, LIP
Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma
This randomized phase II trial studies how well metformin hydrochloride and doxycycline work in treating patients with head and neck squamous cell carcinoma that can be removed by surgery.
- Conditions
- Larynx, LIP, Oral Cavity, Pharynx
- Trial name
- NCT03076281
- Testing
- Metformin Hydrochloride, Doxycycline, Metformin +Doxycycline
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Nasopharyngeal Carcinoma
Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma
To evaluate the effectiveness and safety of Endostar combined with corticosteroids on Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma patients. detailed description:
- Trial name
- NCT05177237
- Testing
- Endostar
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
The goal of this clinical trial is to compare the effectiveness of a navigation-based multilevel intervention (ENDURE) with treatment as usual (TAU) to improve the initiation of guideline-adherent postoperative radiation therapy…
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oral Cavity Cancer
- Trial name
- ENDURE (NCT05793151)
- Testing
- ENDURE
- Where
- 4 sites in United States
- Volunteers
- 532 people
- Sponsor
- Medical University of South Carolina
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.